In September 2025, Cell Envision Biotech was selected as one of the Top 15 finalists in the Taiwan Startup World Cup, emerging from a highly competitive pool of over a hundred startup teams. This competition highlights innovation in deep technology, and our cancer immunotherapy‐adjacent detection and cell‐sorting platform has been acknowledged for its technological prowess.
We specialize in extracting critical tumor and immune signals from blood samples, and have built a liquid‑biopsy platform capable of analyzing the tumor–immune microenvironment. This achievement represents not only a validation of our technology but also marks a milestone as we advance onto the international stage and deepen our product commercialization and clinical translation.
We are committed to leveraging this opportunity to further develop the platform and collaborate with academic, clinical, and industry partners domestically and internationally—aiming to provide a more comprehensive support tool for cancer immunotherapy.
For requests for the technical brief or partnership inquiries, please contact us.